Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 52

Cited In for PubMed (Select 19000821)


CD4 mimetics sensitize HIV-1-infected cells to ADCC.

Richard J, Veillette M, Brassard N, Iyer SS, Roger M, Martin L, Pazgier M, Schön A, Freire E, Routy JP, Smith AB 3rd, Park J, Jones DM, Courter JR, Melillo BN, Kaufmann DE, Hahn BH, Permar SR, Haynes BF, Madani N, Sodroski JG, Finzi A.

Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2687-94. doi: 10.1073/pnas.1506755112. Epub 2015 May 4.


Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.

Sironi F, Malnati M, Mongelli N, Cozzi P, Guzzo C, Ghezzi S, Martínez-Romero C, García-Sastre A, Lusso P, Jabes D, Biswas P.

J Transl Med. 2015 Apr 2;13:107. doi: 10.1186/s12967-015-0461-9.


Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.

Rosemary Bastian A, Nangarlia A, Bailey LD, Holmes A, Kalyana Sundaram RV, Ang C, Moreira DR, Freedman K, Duffy C, Contarino M, Abrams C, Root M, Chaiken I.

J Biol Chem. 2015 Jan 2;290(1):529-43. doi: 10.1074/jbc.M114.608315. Epub 2014 Nov 4.


A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry.

Herschhorn A, Gu C, Espy N, Richard J, Finzi A, Sodroski JG.

Nat Chem Biol. 2014 Oct;10(10):845-52. doi: 10.1038/nchembio.1623. Epub 2014 Aug 31.


Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study.

Curreli F, Kwon YD, Zhang H, Yang Y, Scacalossi D, Kwong PD, Debnath AK.

Antimicrob Agents Chemother. 2014 Sep;58(9):5478-91. doi: 10.1128/AAC.03339-14. Epub 2014 Jul 7.


CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies.

Madani N, Princiotto AM, Schön A, LaLonde J, Feng Y, Freire E, Park J, Courter JR, Jones DM, Robinson J, Liao HX, Moody MA, Permar S, Haynes B, Smith AB 3rd, Wyatt R, Sodroski J.

J Virol. 2014 Jun;88(12):6542-55. doi: 10.1128/JVI.00540-14. Epub 2014 Apr 2.


2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors.

Tiberi M, Tintori C, Ceresola ER, Fazi R, Zamperini C, Calandro P, Franchi L, Selvaraj M, Botta L, Sampaolo M, Saita D, Ferrarese R, Clementi M, Canducci F, Botta M.

Antimicrob Agents Chemother. 2014 Jun;58(6):3043-52. doi: 10.1128/AAC.02739-13. Epub 2014 Mar 10.


Design of antiviral stapled peptides containing a biphenyl cross-linker.

Muppidi A, Zhang H, Curreli F, Li N, Debnath AK, Lin Q.

Bioorg Med Chem Lett. 2014 Apr 1;24(7):1748-51. doi: 10.1016/j.bmcl.2014.02.038. Epub 2014 Feb 22.


Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.

Courter JR, Madani N, Sodroski J, Schön A, Freire E, Kwong PD, Hendrickson WA, Chaiken IM, LaLonde JM, Smith AB 3rd.

Acc Chem Res. 2014 Apr 15;47(4):1228-37. doi: 10.1021/ar4002735. Epub 2014 Feb 6. Review.


Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site.

Kwon YD, LaLonde JM, Yang Y, Elban MA, Sugawara A, Courter JR, Jones DM, Smith AB 3rd, Debnath AK, Kwong PD.

PLoS One. 2014 Jan 28;9(1):e85940. doi: 10.1371/journal.pone.0085940. eCollection 2014.


Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.

Bastian AR, Contarino M, Bailey LD, Aneja R, Moreira DR, Freedman K, McFadden K, Duffy C, Emileh A, Leslie G, Jacobson JM, Hoxie JA, Chaiken I.

Retrovirology. 2013 Dec 13;10:153. doi: 10.1186/1742-4690-10-153.


Blocking HIV-1 gp120 at the Phe43 cavity: if the extension fits….

Dey B, Berger EA.

Structure. 2013 Jun 4;21(6):871-2. doi: 10.1016/j.str.2013.05.004.


Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization.

Lalonde JM, Le-Khac M, Jones DM, Courter JR, Park J, Schön A, Princiotto AM, Wu X, Mascola JR, Freire E, Sodroski J, Madani N, Hendrickson WA, Smith AB 3rd.

ACS Med Chem Lett. 2013 Mar 14;4(3):338-343.


Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans.

Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, Ramos A, Diwanji DC, Pejchal R, Cupo A, Katpally U, Depetris RS, Stanfield RL, McBride R, Marozsan AJ, Paulson JC, Sanders RW, Moore JP, Burton DR, Poignard P, Ward AB, Wilson IA.

PLoS Pathog. 2013;9(5):e1003342. doi: 10.1371/journal.ppat.1003342. Epub 2013 May 2.


HIV-1 envelope glycoprotein structure.

Merk A, Subramaniam S.

Curr Opin Struct Biol. 2013 Apr;23(2):268-76. doi: 10.1016/ Epub 2013 Apr 18. Review.


A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.

Emileh A, Tuzer F, Yeh H, Umashankara M, Moreira DR, Lalonde JM, Bewley CA, Abrams CF, Chaiken IM.

Biochemistry. 2013 Apr 2;52(13):2245-61. doi: 10.1021/bi400166b. Epub 2013 Mar 22.


Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

De Feo CJ, Weiss CD.

Viruses. 2012 Dec;4(12):3859-911. Review.


Peptides presenting the binding site of human CD4 for the HIV-1 envelope glycoprotein gp120.

Meier J, Kassler K, Sticht H, Eichler J.

Beilstein J Org Chem. 2012;8:1858-66. doi: 10.3762/bjoc.8.214. Epub 2012 Oct 31.


Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.

Moseri A, Tantry S, Ding FX, Naider F, Anglister J.

AIDS Res Hum Retroviruses. 2013 Apr;29(4):718-24. doi: 10.1089/AID.2012.0189. Epub 2012 Dec 26.


The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials.

Zabihollahi R, Namazi R, Aghasadeghi MR, Esfahani AF, Sadat SM, Modarressi MH.

Indian J Pharmacol. 2012 Jul-Aug;44(4):448-53. doi: 10.4103/0253-7613.99301.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk